Asset Details
Do you wish to reserve the book?
Neuronal pentraxin Nptx2 regulates complement activity in the brain
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Neuronal pentraxin Nptx2 regulates complement activity in the brain
Do you wish to request the book?
Neuronal pentraxin Nptx2 regulates complement activity in the brain
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Paper
Neuronal pentraxin Nptx2 regulates complement activity in the brain
2022
Overview
Complement overactivation mediates microglial synapse elimination in neurological diseases like Alzheimer disease and frontotemporal dementia (FTD), but how complement activity is regulated in the brain remains largely unknown. We identified that the secreted neuronal pentraxin Nptx2 binds complement C1q and thereby regulates its activity in the brain. Nptx2-deficient mice show increased complement activity and C1q-dependent microglial synapse engulfment and loss of excitatory synapses. In a neuroinflammation culture model and in aged TauP301S mice, AAV-mediated neuronal overexpression of Nptx2 was sufficient to restrain complement activity and ameliorate microglia-mediated synapse loss. Analysis of human CSF samples from a genetic FTD cohort revealed significantly reduced levels of Nptx2 and Nptx2-C1q protein complexes in symptomatic patients, which correlated with elevated C1q and activated C3. Together, these results show that Nptx2 regulates complement activity and microglial synapse elimination in the healthy and diseased brain and that diminished Nptx2 levels might exacerbate complement-mediated neurodegeneration in FTD patients. Competing Interest Statement M.S. is scientific co-founder and member of the SAB of Neumora Therapeutics, and member of the SAB of Biogen, Vanqua Bio, ArcLight Therapeutics, Cerevel Therapeutics. P.F.W. is co-founder of CogNext. J.H. is employed by Genentech. The other authors declare no competing interests.
Publisher
Cold Spring Harbor Laboratory Press,Cold Spring Harbor Laboratory
Subject
